iRhythm Posts Strong Q1 2026 Growth on Volume Demand and Margin Expansion
Event summary
- Q1 2026 revenue rose 25.7% YoY to $199.4M, driven by sustained volume demand across cardiology and primary care markets.
- Gross margin improved 210 basis points to 70.9%, reflecting operational efficiencies and scale benefits from higher volumes.
- Net loss narrowed by $16.8M YoY to $13.9M, with adjusted EBITDA turning positive at $14.1M (7.1% margin).
- Full-year revenue guidance raised to $875M–$885M, with adjusted EBITDA margin now expected at 12.0%–13.0%.
- Cash position stood at $549.6M as of March 31, 2026.
The big picture
iRhythm’s Q1 2026 results highlight the growing demand for digital cardiac monitoring solutions, particularly as healthcare systems prioritize early disease detection. The company’s ability to expand margins while investing in AI and international growth positions it competitively against traditional medical device players like Baxter International. However, sustaining profitability amid rising operational costs remains a key challenge.
What we're watching
- Execution Risk
- Whether iRhythm can sustain its volume-led growth while managing litigation-related expenses and investments in AI-enabled capabilities.
- Market Expansion
- The pace at which international markets contribute to revenue, given the company's increasing diversification across channels.
- Operational Efficiency
- How further scale benefits and cost controls impact gross margin expansion in future quarters.